Not running or cycling — this 10-minute dumbbell workout builds strength and cardiovascular endurance
The CDC recommends that adults get at least 150 minutes of moderate-intensity aerobic exercise per week. While hopping on the treadmill or an elliptical is a great way to do that, sometimes staying stagnant on a machine can get boring.
I actually love a good treadmill run, but pregnancy and childbirth have forced me to take an extended break. I still need to get my daily cardio, though, so I decided to scroll through Instagram for a little inspiration. I landed on fitness influencer Synthia Diane's recent 10-minute workout, and it seemed promising — since I had two dumbbells and 10 minutes to spare, I gave it a try.
If you've just started to work out regularly, I'd recommend meeting with a certified personal trainer before attempting this routine yourself. That goes double for those who are postpartum, like me.
How to do Synthia Diane's 10-minute dumbbell workout
You'll need a pair of light or moderately heavy dumbbells for this workout. If you have both options available, you may want to switch between them depending on the exercise. I used five and ten-pound weights.
There are four exercises in this routine, each done for five reps. You'll circuit through each exercise for as many sets as you can until you reach the 10-minute mark. The exercises are:
Alternating squats
Sumo squats
Triceps extension
Front raises
Since I recently returned to exercise, I expected this routine to be challenging. I was actually surprised by my stamina in the first two sets, so I decided to pick up my pace for the remaining minutes. Here are my other observations after finishing Sythia's workout.
It's easily adaptable for most levels
I love AMRAP ('as many rounds as possible') workouts like this one, and one of the main reasons why is that they're doable for most people. You can go as slow or as fast as you want, take breaks when needed, and push yourself in ways that feel safe and appropriate without falling behind.
Since my first two sets didn't knock me out as much as I thought they would, I decided to pick up my pace for the time I had left. I always felt strong and in control throughout the movements, although I did begin to fatigue by the end. I ended up doing nine sets in 10 minutes, which I'll try to beat the next time I try this workout. That's another reason I love AMRAPs — you can always challenge yourself to complete more rounds on your next try.
If you're advanced, you may want to add more reps
I liked that Synthia kept the moves at five reps each, as that allows you to move quickly through the circuit and keeps things from getting too tedious.
That being said, I felt like I needed a few more reps of each exercise to feel a muscle burn. When I made it to five rounds, I decided to up my reps from five to eight, and that did the trick. If you're no stranger to dumbbell work, you may want to add a few extra reps too.
The upper body exercises were a cardio 'break'
The squat variations definitely got my heart pumping, so it was nice to take a little breather on the tricep extensions and front raises. Because my heart rate dropped and my breathing slowed, I was able to really hone in on my form and make sure my core muscles were engaging properly. When I cycled back to the squats, the brief 'recovery' allowed me to keep my pace up and add some more reps to each round.
This was an observation I can take back to my running practice, when I'm ready. Taking brief intervals where I run slower (or even walk) can keep me going for longer.
My heart rate was elevated, but not as high as when I run
According to my Apple Watch, this workout kept me at around 140-145 beats per minute on average. My heart rate is usually around 155-160 for most of my runs, so I didn't get quite the cardio punch as I do when pounding the pavement.
Still, this was a fantastic full-body strength routine that had some cardiovascular benefits. The 10 minutes went by in a flash, so if you're looking for a quick workout, this could fit the bill.
Benefits of AMRAP workouts
AMRAP workouts are a highly efficient way to build muscular endurance, improve cardiovascular health, and even sharpen your focus. You can go at your own pace and work at your ability level, which means they're appropriate for nearly everyone.
AMRAPS also provides a discernible way to measure your progress. As you get stronger and more conditioned, you will be able to complete a greater number of rounds with each new attempt.
Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
More from Tom's Guide
Forget tight hips — try these 5 mobility moves to unlock stiff hips and build stronger glutes
Ditch crunches — try these 5 kettlebell exercises instead to sculpt your abs, strengthen your core and improve balance
Runners, you need to read this — study suggests a simple training tip could be the key to avoiding injury
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late?
Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks, released its Parnassus Value Equity Fund second-quarter 2025 investor letter. The full letter is available for download here. For the second quarter of 2025, the fund reported a net return of 7.24%, outperforming its benchmark, the Russell 1000 Value Index, which returned 3.79% for the same period. The fund's top 5 holdings are also listed in the letter, showing the firm's main investment positions heading into 2025. One of the companies mentioned in the letter is UnitedHealth Group Inc. (NYSE:UNH). UnitedHealth Group Inc. (NYSE:UNH) operates as a health care company in the United States and internationally. Over the past month, UnitedHealth Group Inc. (NYSE:UNH) fell by -15.12%, and it went down to -54.69% over the last 12 months. On July 29, 2025, UnitedHealth Group Inc. (NYSE:UNH) shares closed at $261.07, with a market value of $236.83 billion. Here is what they have to say about UnitedHealth Group Inc. (NYSE:UNH) in their investor letter: "UnitedHealth Group declined as the company battled with the fallout of missing earnings forecasts and the abrupt resignation of Chief Executive Andrew Witty. We are optimistic that execution will significantly improve with the return of former CEO Stephen Hemsley." Is it Time to Sell UnitedHealth Group (UNH) Before its Too Late? UnitedHealth Group Inc. (NYSE:UNH) ranks 18th in our list of the 30 most popular stocks among hedge funds. According to our data, 139 hedge fund portfolios held positions in UnitedHealth Group Inc. (NYSE:UNH) at the end of the first quarter of 2025, down from 150 in the previous quarter. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. UnitedHealth Group Inc. (NYSE:UNH) ranks 18th in our list of the 30 most popular stocks among hedge funds. According to our data, 139 hedge fund portfolios held positions in UnitedHealth Group Inc. (NYSE:UNH) at the end of the first quarter of 2025, down from 150 in the previous quarter. While we acknowledge the risk and potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UNH and that has 10,000% upside potential, check out our report about this cheapest AI stock. In another article, we covered UnitedHealth Group Inc. (NYSE:UNH) and Barclays analyst Andrew Mok's views on the company in the previous quarter. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA. Date: Wednesday, August 13, 2025Time: 2:00-2:25PM ESTWebcast Link: Canaccord Genuity / Candel Presentation A webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on A replay of the webcast will be archived for up to 90 days following the session date. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). In May 2025, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company's platforms; and expectations regarding the potential benefits conferred by Regenerative Medicine Advanced Therapy Designation, Fast Track Designation, Orphan Drug Designation or Orphan Designation. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor ContactTheodore JenkinsVice President, Investor Relations and Business DevelopmentCandel Therapeutics, Media ContactBen ShannonVice PresidentICR Healthcare CandelPR@ produjo un error al recuperar la información Inicia sesión para acceder a tu portafolio Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información Se produjo un error al recuperar la información


Forbes
24 minutes ago
- Forbes
Beyond The Merger: A Data-Driven Playbook For Healthcare Integration
Dave Albano, President of has more than 35 years of technology industry leadership experience. Mergers and acquisitions (M&As) are accelerating across healthcare—combining hospitals, physician groups, payers and digital health platforms in pursuit of scale, integrated care and better financial performance. However, the value of these deals often hinges on something far less glamorous: how quickly and securely the combined organization can merge and unlock value from inherited data. Meanwhile, M&A is a stress test across three critical domains: • Operational systems—from EHRs to scheduling tools—must be integrated to avoid disruption to patient care and clinician workflows. • Financial systems must be reconciled to ensure billing, revenue cycle management and forecasting remain accurate across legacy platforms. • Compliance requirements must be maintained across both entities, even as policies, access controls and reporting obligations shift under new ownership. In short, M&As create a perfect storm of fragmented systems, increased regulatory scrutiny and pressure to deliver value fast. The Post-M&A Data Landscape With each merger, multiple EHRs, claims systems, analytics tools and governance frameworks converge. This introduces a new layer of complexity, as most systems were built in isolation and weren't designed to talk to each other. Even beyond infrastructure, the business logic within these systems often diverges. Definitions for metrics like "encounter," "denial" or "readmission" can vary significantly. Getting to a shared view of operational performance, financial health and patient outcomes takes more than mapping data fields; it requires reconciling business processes and compliance assumptions. Timelines for these efforts are frequently underestimated. Data unification delays can stretch 12 to 18 months post-close, stalling the very efficiencies the deal was meant to unlock. To avoid these slowdowns, many leading organizations are investing early in centralized data repositories that unify fragmented pipelines, normalize definitions and support near real-time reporting across all departments. Non-Negotiables: Security And Compliance Healthcare data is highly regulated, and M&A activity intensifies those obligations. New data sharing workflows, unfamiliar vendors and transitional access permissions all increase exposure to security and privacy risks. Regulatory requirements such as HIPAA, HITECH and FTC breach notification rules remain in full effect during integration. In addition, state-level privacy laws like the California Consumer Privacy Act (CCPA) or others may apply depending on the entities involved. One common blind spot is user access. Orphaned accounts, inconsistent MFA enforcement and misaligned role definitions can allow unauthorized access to systems or data. Without a rapid, coordinated review of identity and access controls, the merged organization may be out of compliance from day one. The goal isn't just passing an audit. It's building trust with regulators, partners and patients. Organizations that succeed in this phase standardize identity governance across systems, implement centralized audit logging and surface compliance metrics in real time—turning regulatory risk into a managed, measurable process. Operational Challenges Beyond compliance, M&A introduces significant operational pressure. Redundant data pipelines, mismatched formats and unclear lineage slow everything from scheduling and claims to reporting and analytics. Many mid-market organizations rely on a patchwork of point tools or manual workflows—systems that may have worked before the merger but don't scale well under the increased load. The result is duplicated effort, more room for error and difficulty reconciling key performance indicators across the new entity. Even minor inconsistencies in data flows can impact clinical decisions, delay reimbursements or skew forecasts. Business continuity depends on information being not only available but also accurate, consistent and timely. Talent, Turnover And The Mid-Market Gap Post-merger environments often experience talent attrition and shifting roles. Institutional knowledge may walk out the door, and already lean teams are asked to do more with less—sometimes using unfamiliar systems. For mid-sized healthcare organizations, this is a major constraint. Teams can't rely on deep benches of engineers or expensive consultants to carry the weight of integration. That's why scalable, user-friendly platforms—designed around real workflows and supported by continuous feedback loops—are critical to long-term success. When systems are intuitive, front-line adoption increases, training costs fall and institutional knowledge is more easily retained. Bringing Order To The Chaos While no two mergers are alike, successful integrations share a common foundation—a focus on secure, scalable and efficient data unification. Prioritizing the following steps can help organizations avoid disruption, reduce risk and accelerate time to value: 1. Map what you have. Lay the foundation for trust and interoperability. Start by cataloging systems, data sources and access points across both organizations. Identify sensitive data, understand where it resides and how it's currently used. 2. Unify access and oversight. Establish governance that spans the new enterprise. Align access controls using role-based permissions. Ensure governance policies span all environments, including cloud and on-premises systems. 3. Enable seamless data flow. Support clinical accuracy and operational speed. Facilitate timely data exchange between systems to avoid discrepancies or duplication. Ensure updates to records are reflected everywhere they're needed. 4. Monitor critical workflows. Stay ahead of potential disruptions. Implement visibility into key workflows like ETL pipelines and reporting jobs. Early detection of delays or failures prevents downstream disruptions. 5. Automate where you can. Reduce manual effort and strengthen compliance. Use automation to support consistency—especially around access provisioning, audit logging and enforcement of compliance policies. This helps mitigate staffing gaps and reduces manual overhead. M&As can be transformative—but only if the underlying data and systems are securely and intelligently integrated. For healthcare organizations, this isn't just about operational alignment; it's about ensuring continuity of care, protecting patient trust and meeting the regulatory demands that govern the industry. Post-M&A integration must go beyond technical compatibility. It requires creating a unified view of operational and clinical data, delivering real-time insights to front-line care teams and embedding a culture of data-driven decision making from the C-suite to the clinic floor. That means automating manual processes, eliminating data silos and building scalable systems that support care delivery as much as they support compliance and financial stewardship. When done right, integration becomes more than a back-office function—it becomes a driver of better outcomes, faster decisions and more resilient care networks. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?